Ambit Biosciences Inc.'s venture syndicate stepped up for a $30 million Series D-2 round to help support the ongoing Phase II pivotal trial of acute myeloid leukemia (AML) drug AC220 and allow the San Diego-based biotech to avoid the less-than-friendly initial public offering (IPO) market. Read More
Revance Therapeutics Inc. closed a $45 million debt financing and will use the proceeds to advance lead candidate RT001 botulinum toxin type A topical gel, currently in Phase II trials for lateral canthal lines (crow's feet wrinkles) and hyperhidrosis (excessive sweating), and a preclinical injectable botulinum toxin type A product RT002. Read More
WASHINGTON – When it comes to nanotechnology, size does matter, the FDA said in a new draft guidance, which is more of a conversation starter than an actual guidance. Read More
Vertex Pharmaceuticals Inc., of Cambridge, Mass., reported final results from its pivotal Phase III STRIVE study showing that cystic fibrosis (CF) patients treated with VX-770 showed rapid improvements in lung function that were sustained through 48 weeks compared to placebo. Results showed a mean absolute improvement in lung function of 10.6 percent through week 24 and 10.5 percent through week 48. Read More
Biota Scientific Management Pty. Ltd., of Melbourne, Australia, was awarded a five-year, $2.9 million grant from the National Institute of Allergy and Infectious Diseases to fund preclinical development of a candidate for the treatment of Clostridium difficile infection. Read More
Much has been made of both the "gee whiz" and the "oh shoot" possibilities of nanotechnology, but which of them will turn out to be more defining for the technology remains to be seen. Read More
